This inventor holds 2 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Commissariat a L'energie Atomique Et Aux Energies Alternatives, National Institute of Health and Medical Research, Universitè De Montpellier. Active years: 2022-2024.
Company Filing History:
2 out of 8,816 
1 out of 1,853 
1 out of 297 
Years Active: 2022-2024
Title: Innovations by Jean-Philippe Hugnot
Introduction
Jean-Philippe Hugnot is a notable inventor based in Montpellier, France. He has made significant contributions to the field of biomedical research, particularly in the development of antibodies for cancer treatment. With a total of 2 patents, his work focuses on innovative therapeutic solutions.
Latest Patents
Hugnot's latest patents include groundbreaking inventions such as an antibody against the endothelin receptor subtype A. This invention relates to monoclonal antibodies, fragments, or derivatives that can be used therapeutically or diagnostically, especially in the context of cancers like glioblastoma. Another significant patent is for an antibody directed against the endothelin receptor beta sub-type, which also has applications in cancer treatment and research.
Career Highlights
Throughout his career, Jean-Philippe Hugnot has worked with esteemed organizations, including the Commissariat à l'énergie atomique et aux énergies alternatives. His research has been pivotal in advancing the understanding and treatment of various cancers.
Collaborations
Hugnot has collaborated with notable colleagues such as Amaury Herbet and Didier Boquet, contributing to a rich exchange of ideas and innovations in his field.
Conclusion
Jean-Philippe Hugnot's contributions to cancer research through his innovative patents highlight his role as a leading inventor in the biomedical field. His work continues to pave the way for new therapeutic approaches in oncology.